NCBiotech News

Durham-based Qualyst Transporter Systems (QTS) has launched a new test that can steer drug developers away from compounds that could cause liver damage.

Pfizer has committed to providing $4 million to enable the North Carolina Biotechnology Center to establish and administer a  multi-year academic fellowship program to help advance the state's gene therapy expertise.

North Carolina’s world-leading contract research industry got another boost today when INC Research announced plans to move its global headquarters from Raleigh to nearby Morrisville and add 550 jobs over five years.

Almac Group, a global contract research organization (CRO) with 288 employees in Durham, has announced a $5.2 million expansion that will create 79 more jobs over the next three years.

Now is the best time to sign up for your flu shot, and this is the best place to do it. When you reserve a 10-minute “NC Big Shot" slot on the North Carolina Biotechnology Center’s website for the Tuesday, October 4 VaccinatioNCelebration, it’ll reserve your free ticket to participate in a milestone of medicine.

Bamboo Therapeutics, a next-generation gene therapy company based in Chapel Hill, has been acquired by the pharmaceutical giant Pfizer of New York.

Growing demand for natural products by health-conscious consumers has prompted Gaia Herbs to begin a nearly $5 million expansion of its production facilities in Brevard.

Almac Group, a global CRO based in Northern Ireland, has opened a new development facility for companion diagnostics in Durham.

SoBran BioScience, a 500-employee contract research organization based in Fairfax, Va., will open a new animal research facility this summer in Greensboro.

Bamboo Therapeutics, aiming to treat devastating childhood neurological diseases with next-generation gene therapy, is the latest biotechnology company co-founded by entrepreneurs Sheila Mikhail and R. Jude Samulski, Ph.D., director of the Gene Therapy Center at the University of North Carolina at Chapel Hill.

SynShark is using early loan funding from NCBiotech to develop an environmentally sustainable method of harvesting a valuable shark oil called squalene from the leaves of genetically engineered tobacco plants.

In the six years since NCBiotech helped fund the recruitment of Ben Bahr, Ph.D., to head the University of North Carolina at Pembroke's molecular biology and biochemistry program, he has by all accounts earned a robust return on the state’s investment.

The president of Chapel Hill pharmaceutical start-up Eppin Pharmasays a $75,000 loan late last year from the North Carolina Biotechnology Center was an “absolutely critical” lead-in to a $225,000 NIH grant announced today.

North Carolina is one of the world’s leading centers for the manufacture of biologics, pharmaceuticals, vaccines, diagnostics, medical devices and related products.

North Carolina has substantial university and company assets devoted to health informatics, a quickly evolving SuperScieNCe field that uses databases, electronic medical records, bioinformatics and other tools to support clinical decisions that improve health care efficiency, delivery and outcomes.